Related Experiment Video
Updated: Aug 9, 2026
11:49
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Immunosuppression: evolution in practice and trends, 1994-2004
H-U Meier-Kriesche1, S Li, R W G Gruessner
1University of Florida, Gainesville, FL, USA. meierhu@medicine.ufl.edu
Summary
Immunosuppression strategies in solid-organ transplantation have evolved, with increased antibody induction therapy and a shift from cyclosporine to tacrolimus. Acute rejection rates have declined, particularly in kidney recipients.
Area of Science:
- Nephrology
- Immunology
- Transplant Surgery
Background:
- Solid-organ transplantation outcomes are significantly influenced by immunosuppression management.
- Recent advancements in immunosuppressive agents and regimens have reshaped post-transplant care strategies.
Observation:
- Analysis of OPTN/SRTR data reveals key trends in immunosuppression practices over the past decade.
- Increasing use of antibody induction therapy across various solid organs, with highest adoption in kidney and pancreas transplants.
- Tacrolimus/mycophenolate mofetil combination is a prevalent discharge regimen for pancreas transplant recipients.
Findings:
- A notable transition from cyclosporine to tacrolimus as the preferred calcineurin inhibitor for maintenance therapy.
- Steroid-avoidance and withdrawal protocols are gaining traction, though corticosteroids remain common.
- A significant decrease in the incidence of acute rejection episodes within the first year post-transplant, especially for kidney recipients.
Implications:
- These evolving immunosuppression strategies may contribute to improved long-term graft survival and reduced rejection rates.
- The shift towards newer agents and protocols highlights a move towards more personalized and potentially less toxic immunosuppression.
- Continued monitoring and research are essential to optimize immunosuppression regimens for diverse solid-organ transplant recipients.
More Related Videos
Related Concept Videos
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.